Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Core Insights - Incannex Healthcare Inc. has appointed Dr. Alison Wimms as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, representing ResMed [1][3] - Dr. Wimms brings over 20 years of experience in sleep medicine and research, holding a Ph.D. in Medicine and a Master of Medicine in Sleep Medicine from the University of Sydney [2] - The formation of the advisory board and Dr. Wimms' appointment highlight Incannex's commitment to innovation in treating obstructive sleep apnea (OSA) and improving patient outcomes [3] Company Overview - Incannex is focused on developing combination medicines targeting chronic conditions, including OSA, rheumatoid arthritis, and generalized anxiety disorder [6] - The company's lead clinical programs include IHL-42X, an oral fixed-dose combination of acetazolamide and dronabinol, currently in Phase 2/3 clinical studies for OSA [4][6] - IHL-42X has shown promising results in a prior Australian Phase 2 trial, reducing the Apnea-Hypopnea Index (AHI) by an average of 51% at the lowest dose [4] Clinical Development - The global Phase 2/3 clinical trial, named RePOSA, is evaluating IHL-42X in OSA patients who are non-compliant, intolerant, or naïve to positive airway pressure devices [4] - The Phase 2 portion of the trial is being conducted in the United States, with an anticipated top-line readout expected in the first half of 2025 [4] ResMed Overview - ResMed is a pioneer in innovative solutions for chronic diseases, including sleep apnea and COPD, utilizing digital health technologies and cloud-connected medical devices [5] - The company aims to improve quality of life and reduce healthcare costs through its comprehensive out-of-hospital software platforms [5]